Seeking Alpha

Optimer Pharmaceuticals (OPTR) announces positive results from a pair of Phase 3 trials on the...

Optimer Pharmaceuticals (OPTR) announces positive results from a pair of Phase 3 trials on the benefits of its fidaxomicin tablets compared to oral vancomycin for cancer patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector